A major new two-part white paper series from ACD/Labs examines how AI-enabled design-make-test-analyze (DMTA) cycles can overcome fragmented workflows in drug discovery and development. The series discusses how pharma/biotech organizations can leverage automation and informatics technologies to digitalize workflows, empowering faster, robust, and more cost-effective innovation.

ACD/Labs, an informatics company that develops and commercializes software in support of digitalized R&D, today announces the release of a new two-part white paper series, AI-Digital-Physical Convergence: The Future of DMTA in Drug Discovery and Development. The series explores how pharmaceutical organizations can accelerate innovation by modernizing the design-make-test-analyze (DMTA) cycle through AI applications and scientific software working in concert with scientists and the physical experiments they undertake.

The papers describe the transformative potential of an “AI-digital-physical DMTA cycle”— which can help organizations reduce data preparation time for predictive modeling and AI/ML applications from 80% to zero.

Part one focuses on drug discovery and outlines how digital twins and AI can accelerate lead optimization, reduce the burden of manual synthesis design, and improve decision-making across exploratory and confirmatory experimentation. By unifying design, synthesis, testing, and analysis, researchers can shorten the path to identifying viable clinical candidates while maintaining scientific rigor.

Part two discusses the implementation of these principles in pharmaceutical development focusing on Chemistry, Manufacturing, and Controls (CMC). Innovations that accelerate pharmaceutical development can significantly reduce the cost of developing an API into a drug product. AI-augmented DMTA cycles enable organizations to implement quality by design (QbD) principles more effectively; leverage design of experiments (DoE) and Bayesian optimization for iterative and robust design; apply process digital twins for continuous optimization and regulatory readiness; and improve drug substance characterization and drug product formulation with higher reproducibility and compliance.

“The scientific method is being redefined,” said Andrew Anderson, white paper author and Vice President of Innovation and Informatics Strategy at ACD/Labs. “While many R&D organizations are well into their digitalization journeys, most continue to operate in fragmented environments that rely heavily on manual data transfer between systems. This creates inefficiencies, increases the risk of errors, and slows down the transition from scientific insight to clinical reality.”

“We’re increasingly seeing machine-readable data being the work product of experiments to help shorten project timelines. Leaders in Pharmaceutical R&D are striving to enable collaborations with well-structured data—by their scientists, between scientists and machines, and machine-to-machine. In this white paper series, we’re highlighting best practices from the world’s most innovative R&D organizations.”

The white paper series “AI-Digital-Physical Convergence: The Future of DMTA in Drug Discovery and Development” is now available for download

View White Paper Series

About ACD/Labs

ACD/Labs is a leading provider of scientific software, aiding decision-making and digital transformation in chemical and pharmaceutical R&D.

Our science-centric solutions offer harmonized, AI-ready analytical, structural, and molecular information, with FAIR-compliance. Our cloud-enabled technologies enable the proliferation of chemically intelligent knowledge and workflow automation.

For >30 years, we have partnered with global organizations to enhance productivity and accelerate scientific innovation

Recent news from ACD/Labs